(SeaPRwire) – The funds will hasten the preclinical verification of biofabricated tissue implants designed for soft tissue repair, wound healing, and trauma management, while simultaneously establishing the biological and manufacturing bases for 3D-bioprinted functional human organs.
Berlin / Boston – 25 March, 2026 – In cases of severe soft tissue loss, complex wounds like full-thickness burns or blast injuries, and reconstructive defects, current medical treatments often rely on compromises. These include invasive grafting procedures and synthetic implants that may imperfectly restore shape but rarely restore living function.
Cellbricks Therapeutics is dedicated to altering this reality. The company has revealed new financing that will power the next phase of translational development for its biofabricated human tissue implants, moving living, vascularized tissue constructs through strict preclinical validation and closer to clinical application.
This financing consists of a €7 million seed round and over €3 million in extra non-dilutive funding currently being finalized. Significantly, it grants Cellbricks Therapeutics the capacity to perform the essential work required for advancement in this field: progressing its lead adipose tissue implant program, initiating up to three preclinical animal studies, and creating the evidence necessary to approach human clinical trials.
The primary focus of Cellbricks Therapeutics is on significant unmet needs in reconstructive surgery, wound healing, and trauma care. Its leading adipose tissue implant program targets complex soft tissue defects and provides biological options to synthetic implants, including for breast reconstruction. For both clinicians and patients, the necessity is apparent: superior repair, integration, and functional outcomes.
The long-term vision is even greater: 3D-bioprinted viable human organs. However, the path to this future is not defined by a single breakthrough. It is a gradual process of solving biological, engineering, and translational challenges, tissue by tissue. Living implants that survive, vascularize, integrate, and function within the body are the crucial stepping stones.
This new funding is pivotal. It enables Cellbricks Therapeutics to shift from potential to proof: demonstrating that engineered human tissues can perform in clinically relevant models and establishing a viable path from today’s advanced tissue implants to future organ replacement.
The round was spearheaded by Silicon Roundabout Ventures, with involvement from Germany’s Federal Agency for Breakthrough Innovation (SPRIND), as well as current investors ACT Venture Partners and a group of long-term investors supporting Cellbricks’ mission.
“Our goal is clear: restoring functional human tissue and, ultimately, making organ replacement possible. That future is built through disciplined milestones. This capital enables us to reach the next stage of validation and to advance living tissue implants that meet urgent patient needs now, while also preparing for what lies ahead.”
Alexander Leutner, Co-CEO and Co-Founder, Cellbricks Therapeutics
“Regenerative medicine has long discussed theoretical possibilities. The next chapter is about proving what works in relevant models, using living tissues designed to integrate, restore function, and move toward the clinic with genuine credibility.”
Dr. Simon MacKenzie, Co-CEO, Cellbricks Therapeutics
Cellbricks Therapeutics has engineered a proprietary biofabrication platform that produces vascularized human tissue implants. As it advances translational development, the company continues to expand within the leading innovation ecosystems of Berlin and Boston.
This capital speeds up execution where it is most critical: faster preclinical validation, stronger translational data, and a more credible route toward a defining goal for the field that has remained out of reach for too long.
About Cellbricks Therapeutics
Cellbricks Therapeutics is a tissue engineering firm focused on creating biofabricated human tissue implants for regenerative medicine. By using a proprietary biofabrication platform, the company engineers vascularized human tissue therapeutics aimed at restoring function in patients with severe tissue damage, including complex wounds and soft tissue defects, with long-term goals in organ repair and replacement. www.cellbricks-therapeutics.com
About Silicon Roundabout Ventures
Silicon Roundabout Ventures are committed to hard challenges. We are the venture capital fund for European deep-tech founders building critical infrastructure. Having grown from a London pub meetup into a community of 15,000 scientists and engineers, we avoid superficial trends. We relentlessly search our network to provide the first checks for the brightest technical minds building in critical industries like computing, energy, and defence. www.siliconroundabout.ventures
About SPRIND
SPRIND, the German Federal Agency for Breakthrough Innovation, was founded in 2019 to support groundbreaking technologies and innovations that can significantly improve lives and address the major challenges of our time. Every year, SPRIND invests about €250 million in European breakthrough technologies, helping visionary ideas move from development to market launch. www.sprind.org
About ACT Venture Partners
ACT Venture Partners is a European venture capital firm that specializes in early-stage investments for deep-tech startups, with team members in Amsterdam, London, and Istanbul. Besides providing capital, ACT offers strategic support in fundraising, hiring, and public policy, helping to turn innovative tech ideas into global businesses. www.actvp.vc
Contacts & Photos
| Media & Lab Visit Moritz Marschall mm@cellbricks.com +49 176 999 26426 |
Investor Relations Alexander Leutner al@cellbricks.com +49 178 3200822 |
Attachments
- Cellbricks freshly 3d-bioprinted tissue implant
- Cellbricks prepared tissue implant
- Cellbricks Team at Berlin Headquarters
- Cellbricks tissue engineers with biofabricated tissue implant
CONTACT: Investor Relations Alexander Leutner al@cellbricks.com +49 178 3200822
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.